Free Trial

Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Drops By 26.2%

Neuronetics logo with Medical background

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 2,700,000 shares, a drop of 26.2% from the April 30th total of 3,660,000 shares. Approximately 9.9% of the company's shares are short sold. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 2.4 days.

Neuronetics Trading Up 1.3%

Neuronetics stock traded up $0.05 during mid-day trading on Tuesday, reaching $3.86. 393,556 shares of the company traded hands, compared to its average volume of 755,854. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics has a 52-week low of $0.52 and a 52-week high of $5.92. The firm has a market capitalization of $254.07 million, a price-to-earnings ratio of -3.14 and a beta of 1.92. The firm's 50 day moving average price is $4.04 and its 200 day moving average price is $3.20.

Neuronetics (NASDAQ:STIM - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. The company had revenue of $31.98 million for the quarter, compared to analysts' expectations of $29.07 million. On average, analysts anticipate that Neuronetics will post -1.13 earnings per share for the current fiscal year.

Insider Transactions at Neuronetics

In other news, EVP Stephen Furlong sold 193,460 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the sale, the executive vice president now directly owns 416,593 shares in the company, valued at approximately $1,778,852.11. This represents a 31.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in STIM. JPMorgan Chase & Co. boosted its position in shares of Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock valued at $88,000 after purchasing an additional 54,442 shares in the last quarter. Tradewinds LLC. purchased a new position in Neuronetics during the fourth quarter valued at $32,000. Geode Capital Management LLC boosted its holdings in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock valued at $506,000 after buying an additional 8,466 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Neuronetics during the 4th quarter valued at $49,000. Finally, Balyasny Asset Management L.P. grew its position in shares of Neuronetics by 29.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after buying an additional 337,539 shares during the period. Institutional investors own 53.59% of the company's stock.

Analyst Ratings Changes

Separately, Canaccord Genuity Group increased their price objective on Neuronetics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th.

Get Our Latest Stock Analysis on Neuronetics

Neuronetics Company Profile

(Get Free Report)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

See Also

Should You Invest $1,000 in Neuronetics Right Now?

Before you consider Neuronetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neuronetics wasn't on the list.

While Neuronetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines